These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24582729)

  • 21. Mismatched human leukocyte antigen class II-restricted CD8⁺ cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation.
    Hirosawa T; Torikai H; Yanagisawa M; Kamei M; Imahashi N; Demachi-Okamura A; Tanimoto M; Shiraishi K; Ito M; Miyamura K; Shibata K; Kikkawa F; Morishima Y; Takahashi T; Emi N; Kuzushima K; Akatsuka Y
    Cancer Sci; 2011 Jul; 102(7):1281-6. PubMed ID: 21466613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.
    Amir AL; Hagedoorn RS; van Luxemburg-Heijs SA; Marijt EW; Kruisselbrink AB; Frederik Falkenburg JH; Heemskerk MH
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):210-9. PubMed ID: 22015995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of human cytomegalovirus-specific CD8+ T-cells in allogeneic haematopoietic stem cell transplant recipients using pentamer and interferon-γ-enzyme-linked immunospot assays.
    Liu A; Ma Y; Wu W; Chen X; Huang Y; Hu J; Liang H; Wang H; Yang R; Fan J
    J Clin Virol; 2013 Oct; 58(2):427-31. PubMed ID: 23910932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
    Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
    Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
    Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minor histocompatibility antigens: past, present, and future.
    Spierings E
    Tissue Antigens; 2014 Oct; 84(4):374-60. PubMed ID: 25262921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent allorecognition has a limited impact on posttransplant vaccination.
    Manzo T; Hess Michelini R; Basso V; Ricupito A; Chai JG; Simpson E; Bellone M; Mondino A
    J Immunol; 2011 Feb; 186(3):1361-8. PubMed ID: 21209285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
    Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
    Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation.
    Wölfel C; Lennerz V; Lindemann E; Hess G; Derigs HG; Huber C; Herr W; Wölfel T
    Cancer Immunol Immunother; 2008 Jun; 57(6):849-57. PubMed ID: 18004563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minor histocompatibility antigen UTY as target for graft-versus-leukemia and graft-versus-haematopoiesis in the canine model.
    Bund D; Buhmann R; Gökmen F; Zorn J; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2013 Jan; 77(1):39-53. PubMed ID: 23126655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation.
    Fuchs KJ; Falkenburg JHF; Griffioen M
    Best Pract Res Clin Haematol; 2024 Jun; 37(2):101555. PubMed ID: 39098803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive transfer of allogeneic antigen-specific T cells.
    Riddell SR; Bleakley M; Nishida T; Berger C; Warren EH
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):9-12. PubMed ID: 16399578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered homeostasis of CD4(+) memory T cells in allogeneic hematopoietic stem cell transplant recipients: chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell pool.
    Fukunaga A; Ishikawa T; Kishihata M; Shindo T; Hori T; Uchiyama T
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1176-84. PubMed ID: 17889354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation.
    Spierings E; Vermeulen CJ; Vogt MH; Doerner LE; Falkenburg JH; Mutis T; Goulmy E
    Lancet; 2003 Aug; 362(9384):610-5. PubMed ID: 12944060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.
    Bleakley M; Otterud BE; Richardt JL; Mollerup AD; Hudecek M; Nishida T; Chaney CN; Warren EH; Leppert MF; Riddell SR
    Blood; 2010 Jun; 115(23):4923-33. PubMed ID: 20203263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minor histocompatibility antigen DDX3Y induces HLA-DQ5-restricted T cell responses with limited TCR-Vbeta usage both in vivo and in vitro.
    Laurin D; Spierings E; van der Veken LT; Hamrouni A; Falkenburg JH; Souillet G; Vermeulen C; Farre A; Galambrun C; Rigal D; Bertrand Y; Goulmy E; Eljaafari A
    Biol Blood Marrow Transplant; 2006 Nov; 12(11):1114-24. PubMed ID: 17085304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.